# Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)

> **NCT06917911** · PHASE2 · NOT_YET_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 162 (estimated)

## Conditions studied

- Core Binding Factor Acute Myeloid Leukemia

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin Hydrochloride
- **PROCEDURE:** Echocardiography Test
- **DRUG:** Gemtuzumab Ozogamicin
- **PROCEDURE:** Multigated Acquisition Scan
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT06917911
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-18
- **Primary completion:** 2027-11-25
- **Final completion:** 2027-11-25
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06917911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06917911, "Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06917911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*